HIM
ADPT icon

Hillsdale Investment Management’s Adaptive Biotechnologies ADPT Stock Holding History

Hillsdale Investment Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.68M Buy
625,217
+8,267
+1% +$132K 0.24% 76
2025
Q4 		$10M Sell
616,950
-4,840
-0.8% -$79K 0.28% 57
2025
Q3 		$9.3M Buy
621,790
+53,700
+9% +$654K 0.28% 60
2025
Q2 		$6.62M Buy
+568,090
New +$5.16M 0.24% 82

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Hillsdale Investment Management's ADPT Position: Q1 2026 in Review

Hillsdale Investment Management increased its Adaptive Biotechnologies (ADPT) stake by 1.3% in Q1 2026, buying an estimated $132K and bringing the position to 625,217 shares worth $8.68M. The position accounts for 0.24% of the portfolio, ranked #76.

Hillsdale Investment Management first reported a position in ADPT in Q2 2025 and has held it in 4 quarters since. The position peaked at $10M in Q4 2025. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Hillsdale Investment Management held 625,217 shares of Adaptive Biotechnologies worth $8.68M as of Q1 2026.
  • Hillsdale Investment Management bought 8,267 Adaptive Biotechnologies shares in Q1 2026, an estimated $132K.
  • Adaptive Biotechnologies made up 0.24% of Hillsdale Investment Management's portfolio in Q1 2026, its #76 holding.
  • Hillsdale Investment Management first reported a position in Adaptive Biotechnologies in Q2 2025 and has held it in 4 quarters since.
  • Hillsdale Investment Management's Adaptive Biotechnologies position peaked at $10M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.